title: Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
abstract: BACKGROUND
  Surgical indication for metastatic gastrointestinal stromal tumor (GIST) treated with imatinib is not yet established.
  
  
  METHODS
  We analyzed 80 patients who underwent surgery for metastatic GIST after imatinib therapy from July 2002 to October 2007. Patients were divided into those with surgery at best clinical response (group A, n = 49) and those with surgery at focal progression (group B, n = 31). Primary end points were progression-free survival (PFS) and disease-specific survival (DSS).
  
  
  RESULTS
  Two-year postoperative PFS was 64.4% in group A and 9.7% in group B (P < 0.01). In group A, median PFS was not reached; in group B, it was 8 months. Median DSS from the time of imatinib onset was not reached in either group. Five-year DSS was 82.9% in group A and 67.6% in group B (P < 0.01). Multivariate analysis confirmed a significantly shorter PFS and DSS in group B. Surgical morbidity occurred in 13 patients (16.3%).
  
  
  CONCLUSIONS
  Surgery for focal progressive lesions could be considered as part of the second-line/third-line armamentarium in selected cases. Surgery of residual disease upon best clinical response seems associated with survival benefit compared with historical controls in similar patient collectives treated with imatinib alone. However, evidence from prospective randomized trials is needed to make definite recommendations.
authors.affiliation: Melanoma and Sarcoma Unit, Department of Surgery, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Mussi
authors.affiliation: Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Ronellenfitsch
authors.affiliation: Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Jakob
authors.affiliation: Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Tamborini
authors.affiliation: Department of Hematology, Oncology and Palliative Care, HELIOS Medical Center, Bad Saarow, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Reichardt
authors.affiliation: Department of Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: P G
authors.initials: PG
authors.lastname: Casali
authors.affiliation: Melanoma and Sarcoma Unit, Department of Surgery, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Fiore
authors.affiliation: Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Hohenberger
authors.affiliation: Melanoma and Sarcoma Unit, Department of Surgery, Istituto Nazionale Tumori, Milan, Italy. Electronic address: alessandro.gronchi@istitutotumori.mi.it.
authors.forename: A
authors.initials: A
authors.lastname: Gronchi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D018447:Medical Futility; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate